Abstract
Introduction: Pathological remodeling of the cardiac extracellular matrix (ECM) post-myocardial infarction (MI) is a key contributor to heart failure (HF). Injectable biomaterials are of clinical interest as they can limit remodeling and stimulate infarct repair. Our objective was to test the ability of the first injectable hydrogel formulations of recombinant human collagen type I (rHCI) and type III (rHCIII) to improve cardiac function post-MI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
